Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension at World Sleep 2025

Core Insights - Avadel Pharmaceuticals presented new data on LUMRYZ, a once-nightly sodium oxybate treatment for narcolepsy, at World Sleep 2025, highlighting its efficacy in improving symptoms for both new and returning patients [1][2][3] Group 1: Efficacy of LUMRYZ - The REFRESH study demonstrated that patients switching from twice-nightly oxybate to LUMRYZ experienced clinically meaningful improvements in excessive daytime sleepiness (EDS) and other narcolepsy symptoms [4] - 70% of switch participants and 90% of non-switch participants reported improvement on the Patient Global Impression of Change after 4 months of therapy [4] - The study also indicated a reduction in severity of narcolepsy symptoms from moderate to mild, with significant improvements in quality of life metrics such as fatigue, brain fog, and mood [4] Group 2: Presentation Highlights - A total of 17 abstracts were accepted for presentation at World Sleep 2025, including one oral presentation and 16 posters, focusing on the benefits of LUMRYZ [1][2] - Presentations reinforced the advantages of LUMRYZ in addressing hallmark symptoms of narcolepsy, including EDS and sleep-related hallucinations [3] Group 3: Regulatory and Market Position - LUMRYZ is the first and only once-at-bedtime treatment for cataplexy or EDS in patients aged seven years and older with narcolepsy, receiving FDA approval in May 2023 and October 2024 [8][10] - The FDA granted LUMRYZ seven years of Orphan Drug Exclusivity due to its clinical superiority over existing treatments, emphasizing its once-nightly dosing regimen [10]